For the first time in history, health R&D investments stagnate in Europe since 2010, after decades of increase, reports Deloitte on behalf of Janssen.
To put this in perspective, 60% of the 47 billion euros invested in 2011 were by the pharmaceutical industry and 40% by member states - this amount being 3% of EU total healthcare expenditure.
Private investments have stagnated for the first time, while public investments decreased by 1% - US investment decreased even more sharply, but (...)

“Medical biotechnologies”, “Digital hospital”, and “New Medical Devices” appear among the 34 plans of “industrial recovery” presented by the French president on the 12th of September at Elysée Palace.
McKinsey estimated the potential of these 34 plans to be 480,000 jobs in 10 years and 45.5 billion Euros of generated value – 40% of which for exportation.
The plan “Medical Biotechnologies” will allow the reinforcement of France’s position in terms of synthetic biotechnology and cell therapy by (...)